Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Third party research

Lipum: Merging with Flerie - VH Corp

Lipum

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
* Flerie has proposed a merger with Lipum
* Topline data support BSSL’s role in RA
* Our model suggests a fair value of SEK 16.29 per share

A key issue in Lipum’s preparations for the anticipated phase II study has been the financing. This will now likely be resolved in a different setting, after a suggested merger with the main shareholder, Flerie. The plan is supported by other major shareholders representing 16.5 per cent in addition to Flerie’s holding of 57 per cent. During the quarter, Lipum announced new topline data in its collaboration with Linköping University. The data show that the levels of bile salt-stimulated lipase in rheumatoid arthritis patients correspond to disease activity. The findings support Lipum’s clinical development of SOL-116.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.